Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease 

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib

A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer

Breast cancer in elderly patients: a clinicopathological review of a Nigerian database

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease